Cargando…

Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen

BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib (BTZ), melphalan, and prednisone (VMP) regimen and regimens without BTZ. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Hee-Jeong, Seo, Sang-Kyung, Baek, Dong Won, Park, Sung-Woo, Lee, Yoo-Jin, Sohn, Sang-Kyun, Lee, Ho-Sup, Lee, Won Sik, Lee, Ji Hyun, Kim, Sung Hyun, Moon, Joon-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yeungnam University College of Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784679/
https://www.ncbi.nlm.nih.gov/pubmed/31620574
http://dx.doi.org/10.12701/yujm.2018.35.1.76
_version_ 1783457792188743680
author Cho, Hee-Jeong
Seo, Sang-Kyung
Baek, Dong Won
Park, Sung-Woo
Lee, Yoo-Jin
Sohn, Sang-Kyun
Lee, Ho-Sup
Lee, Won Sik
Lee, Ji Hyun
Kim, Sung Hyun
Moon, Joon-Ho
author_facet Cho, Hee-Jeong
Seo, Sang-Kyung
Baek, Dong Won
Park, Sung-Woo
Lee, Yoo-Jin
Sohn, Sang-Kyun
Lee, Ho-Sup
Lee, Won Sik
Lee, Ji Hyun
Kim, Sung Hyun
Moon, Joon-Ho
author_sort Cho, Hee-Jeong
collection PubMed
description BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib (BTZ), melphalan, and prednisone (VMP) regimen and regimens without BTZ. METHODS: One-hundred and forty elderly patients who were diagnosed with MM from March 2007 to March 2015 were included in this retrospective study. To evaluate regimen adherence, patients who were treated with more than 4 cycles were assigned to the good adherence group. RESULTS: Among the 140 patients, 71 were treated with a frontline VMP and 69 with non-BTZ regimens. The median age was 71 years (range, 65-90 years). The VMP group showed a higher complete response rate than the non-BTZ group: 26.8% vs. 7.2%. More patients in the VMP group achieved ≥very good partial response (VGPR) and ≥PR. In the VMP group, 27 patients (38.0%) received less than 4 cycles. The VMP good adherence group showed a higher 3-year overall survival (OS) rate (70.9%) than the poor adherence group (60.2%, p=0.059). In the multivariate analysis, treatment with ≥4 cycles of VMP was a favorable factor for OS. CONCLUSION: A good adherence to a frontline VMP regimen resulted in favorable long-term survival. Adequate management of AEs will be needed to achieve favorable outcomes in elderly patients with MM.
format Online
Article
Text
id pubmed-6784679
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Yeungnam University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-67846792019-10-16 Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen Cho, Hee-Jeong Seo, Sang-Kyung Baek, Dong Won Park, Sung-Woo Lee, Yoo-Jin Sohn, Sang-Kyun Lee, Ho-Sup Lee, Won Sik Lee, Ji Hyun Kim, Sung Hyun Moon, Joon-Ho Yeungnam Univ J Med Original Article BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib (BTZ), melphalan, and prednisone (VMP) regimen and regimens without BTZ. METHODS: One-hundred and forty elderly patients who were diagnosed with MM from March 2007 to March 2015 were included in this retrospective study. To evaluate regimen adherence, patients who were treated with more than 4 cycles were assigned to the good adherence group. RESULTS: Among the 140 patients, 71 were treated with a frontline VMP and 69 with non-BTZ regimens. The median age was 71 years (range, 65-90 years). The VMP group showed a higher complete response rate than the non-BTZ group: 26.8% vs. 7.2%. More patients in the VMP group achieved ≥very good partial response (VGPR) and ≥PR. In the VMP group, 27 patients (38.0%) received less than 4 cycles. The VMP good adherence group showed a higher 3-year overall survival (OS) rate (70.9%) than the poor adherence group (60.2%, p=0.059). In the multivariate analysis, treatment with ≥4 cycles of VMP was a favorable factor for OS. CONCLUSION: A good adherence to a frontline VMP regimen resulted in favorable long-term survival. Adequate management of AEs will be needed to achieve favorable outcomes in elderly patients with MM. Yeungnam University College of Medicine 2018-06-30 /pmc/articles/PMC6784679/ /pubmed/31620574 http://dx.doi.org/10.12701/yujm.2018.35.1.76 Text en Copyright © 2018 Yeungnam University College of Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Cho, Hee-Jeong
Seo, Sang-Kyung
Baek, Dong Won
Park, Sung-Woo
Lee, Yoo-Jin
Sohn, Sang-Kyun
Lee, Ho-Sup
Lee, Won Sik
Lee, Ji Hyun
Kim, Sung Hyun
Moon, Joon-Ho
Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
title Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
title_full Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
title_fullStr Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
title_full_unstemmed Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
title_short Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
title_sort chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784679/
https://www.ncbi.nlm.nih.gov/pubmed/31620574
http://dx.doi.org/10.12701/yujm.2018.35.1.76
work_keys_str_mv AT choheejeong chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen
AT seosangkyung chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen
AT baekdongwon chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen
AT parksungwoo chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen
AT leeyoojin chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen
AT sohnsangkyun chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen
AT leehosup chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen
AT leewonsik chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen
AT leejihyun chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen
AT kimsunghyun chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen
AT moonjoonho chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen